Table 4.
Group | Antimicrobial resistance profile | Number of isolates | ||
---|---|---|---|---|
MSSA, n = 93 | MRSA, n = 40 | Total, ∗N = 139 (%) | ||
1 | STX | 1 | — | 1 (0.7) |
2 | TE | 1 | — | 1 (0.7) |
3 | P | 27 | 3 | 30 (21.6) |
4 | P, CLO | 1 | — | 1 (0.7) |
5 | P, CN | 1 | — | 1 (0.7) |
6 | P, STX | 2 | — | 2 (1.4) |
7 | P, E | 5 | 1 | 6 (4.3) |
8 | P, DA | 1 | — | 1 (0.7) |
9 | E, DA | 5 | — | 5 (3.6) |
10 | P, E, FOX | — | 1 | 1 (0.7) |
11 | P, FOX, OX | — | 1 | 1 (0.7) |
12 | P, E, STX | 1 | 1 | 2 (1.4) |
13 | P, E, CIP | 1 | — | 1 (0.7) |
14 | P, E, DA | 32 | 11 | 43 (30.9) |
15 | P, E, CN | 1 | — | 1 (0.7) |
16 | P, DA, FOX | — | 1 | 1 (0.7) |
17 | P, CIP, RD | 1 | — | 1 (0.7) |
18 | P, E, DA, FOX | — | 3 | 3 (2.2) |
19 | P, E, DA, OX | — | 7 | 7 (5.0) |
20 | P, E, DA, STX | 3 | 1 | 4 (2.9) |
21 | P, E, DA, CIP | 2 | — | 2 (1.4) |
22 | P, E, DA, CN | 2 | — | 2 (1.4) |
23 | P, E, DA, TE | 1 | — | 1 (0.7) |
24 | P, E, STX, TE | — | 1 | 1 (0.7) |
25 | P, E, DA, FOX, OX | — | 1 | 1 (0.7) |
26 | P, E, DA, STX, TGC | 1 | — | 1 (0.7) |
27 | P, E, DA, CN, TE | 1 | — | 1 (0.7) |
28 | P, E, DA, FOX, CIP | — | 1 | 1 (0.7) |
29 | P, E, DA, FOX, CN | — | 1 | 1 (0.7) |
30 | P, E, STX, CIP, TE | 1 | — | 1 (0.7) |
31 | P, E, DA, STX, CN | 1 | — | 1 (0.7) |
32 | P, E, DA, FOX, OX, CN | — | 1 | 1 (0.7) |
33 | P, E, DA, FOX, OX, LZD | — | 1 | 1 (0.7) |
34 | P, E, DA, FOX, CIP, CN | — | 1 | 1 (0.7) |
35 | P, E, DA, FOX, CN, TE | — | 1 | 1 (0.7) |
36 | P, E, DA, FOX, CIP, CN, TE | — | 1 | 1 (0.7) |
37 | P, E, DA, FOX, OX, CIP, CLO | — | 1 | 1 (0.7) |
38 | P, E, DA, STX, CN, CIP, CLO, TE | 1 | — | 1 (0.7) |
∗Six isolates were susceptible to all antimicrobial tested. P: penicillin (10 U); FOX: cefoxitin (30 µg); CLO: chloramphenicol (30 µg); CIP: ciprofloxacin (5 µg); DA: clindamycin (2 µg); E: erythromycin (15 µg); CN: gentamicin (10 µg); LZD: linezolid (30 µg); RD: rifampicin (5 µg) STX: sulfamethoxazole/trimethoprim (23.75/1.25 µg); TE: tetracycline (30 µg); TGC: tigecycline (15 µg). —: not detected.